FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
Published Online: 2016-10-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Alexander Kiani•Andreas Jagenburg•Andreas Jung•Christian Lerchenmüller•Christoph Kahl•Clemens Giessen-Jung•Dominik P Modest•Frank Kullmann•Gernot Seipelt•Lisa Rossius•Ludwig Fischer von Weikersthal•Markus M Lerch•Markus Moehler•Martina Stauch•Salah-Eddin Al-Batran•Sebastian Stintzing•Swantje Held•Thomas Decker•Thomas Kirchner•Tobias Heintges•Ursula Vehling-Kaiser•Volker Heinemann•Werner Scheithauer
